APA
Ghatnekar O., Nørgaard K. & Skaltsa K. (20160610). Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC). : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Chicago
Ghatnekar O, Nørgaard K and Skaltsa K. 20160610. Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC). : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Harvard
Ghatnekar O., Nørgaard K. and Skaltsa K. (20160610). Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC). : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
MLA
Ghatnekar O, Nørgaard K and Skaltsa K. Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC). : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20160610.